Popular search terms:
Search Results Label
42 results found-
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
https://www.seqirus.us/news/seqirus-receives-fda-approval-for-fluad-quadrivalent-for-adults-65-years-and-older -
Seqirus Releases First Shipment for 2019 2020 Season
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.
https://www.seqirus.us/news/seqirus-releases-first-shipment-for-2019-2020-season -
Seqirus Presents Data at IDWeek Demonstrating Cell Derived Viruses
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
https://www.seqirus.us/news/seqirus-presents-data-at-idweek-demonstrating-cell-derived-viruses -
New Clinical Data Reinforces the Ability of MF59 Adjuvanted Seasonal and Pandemic Influenza Vaccines
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
https://www.seqirus.us/news/new-clinical-data-reinforces-the-ability-of-mf59-adjuvanted-seasonal-and-pandemic-influenza-vaccines -
Seqirus Begins Shipping 2018 2019 Influenza Vaccines to the US Market
Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market
https://www.seqirus.us/news/seqirus-begins-shipping-2018-2019-influenza-vaccines-to-the-us-market -
New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
https://www.seqirus.us/news/new-scientific-data-comparing-circulating-influenza-b-viruses -
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine FLUAD
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
https://www.seqirus.us/news/seqirus-presents-favorable-outcomes-data-for-adjuvanted-trivalent-influenza-vaccine-fluad -
Seqirus | Latest News
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news -
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/seqirus-begins-shipping-2017-2018-influenza-vaccines -
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
https://www.seqirus.us/news/seqirus-receives-fda-approval-of-afluria-quadrivalent-for-six-months-of-age-and-older